Blomgren H, Blom U, Ullén H
Anticancer Res. 1985 Jul-Aug;5(4):349-54.
Sera from 125 untreated patients with various histological types of primary intracranial tumors were examined for the capacity to support proliferative responses of lymphocytes to PHA and PPD in vitro. It was observed that sera obtained from groups of non-corticosteroid treated patients with astrocytomas, malignant gliomas (anaplastic astrocytomas and glioblastomas), and miscellaneous tumors (mainly meningiomas) did not differ significantly from sera obtained from a group of healthy subjects. However, sera from a group of patients with oligodendrogliomas exhibited a significantly reduced capacity to support PHA- and PPD-responses of both autologous and allogeneic lymphocytes. Corticosteroid treated patients seemed to have reduced serum activities regardless of histological tumor type. It is not known whether sera from patients with oligodendrogliomas contain increased amounts of factors which inhibit mitogen responses of lymphocytes, or whether they contain reduced amounts of factors which support stimulations in vitro.
检测了125例未经治疗的各种组织学类型原发性颅内肿瘤患者的血清,以评估其在体外支持淋巴细胞对PHA和PPD增殖反应的能力。观察到,来自未接受皮质类固醇治疗的星形细胞瘤、恶性胶质瘤(间变性星形细胞瘤和胶质母细胞瘤)以及其他肿瘤(主要是脑膜瘤)患者组的血清,与来自一组健康受试者的血清相比,无显著差异。然而,来自一组少突胶质细胞瘤患者的血清,在支持自体和异体淋巴细胞对PHA和PPD反应方面,能力显著降低。无论肿瘤的组织学类型如何,接受皮质类固醇治疗的患者血清活性似乎都有所降低。尚不清楚少突胶质细胞瘤患者的血清中是否含有更多抑制淋巴细胞有丝分裂原反应的因子,或者是否含有更少支持体外刺激的因子。